Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have ulcerative colitis diagnosed by a doctor with a colonoscopy.
- You have had at least 6 bloody bowel movements a day in the past week and at least one other sign of severe inflammation (like fever, fast heart rate, low red blood cells, or high inflammation markers).
- You have not taken upadacitinib before.
- You are willing to take oral medication and attend study visits.
- If you could become pregnant, you must have a negative pregnancy test and use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different sequences of medicines for treating severe ulcerative colitis flares in the hospital. It aims to find the best way to get your symptoms under control and help you feel better faster.
This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study tests whether upadacitinib, a pill that calms the immune system, can help people hospitalized with a severe flare of ulcerative colitis. It aims to see if the drug can reduce symptoms and help you leave the hospital sooner.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
Hear when a new Ulcerative Colitis Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.